Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.

ABSTRACT:

Background

Intravenous Ig (IVIg), plasma exchange, and immunoadsorption are frequently used in the management of severe autoimmune diseases mediated by pathogenic IgG autoantibodies. These approaches modulating IgG levels can, however, be associated with some severe adverse reactions and a substantial burden to patients. Targeting the neonatal Fc receptor (FcRn) presents an innovative and potentially more effective, safer, and more convenient alternative for clearing pathogenic IgGs.

Methods

A randomized, double-blind, placebo-controlled first-in-human study was conducted in 62 healthy volunteers to explore single and multiple ascending intravenous doses of the FcRn antagonist efgartigimod. The study objectives were to assess safety, tolerability, pharmacokinetics, pharmacod

SUBMITTER: Ulrichts P 

PROVIDER: S-EPMC6159959 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature